Dow Jones

40 003,59

0,34%

DAX

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

S'inscrire

AKLI

Akili (AKLI)

Akili Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:AKLI

1 2 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
14/05/2024	22h16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:AKLI	Akili Inc
14/05/2024	22h10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AKLI	Akili Inc
14/05/2024	22h01	Business Wire	Akili Reports First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:AKLI	Akili Inc
06/05/2024	23h32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AKLI	Akili Inc
30/04/2024	14h00	Business Wire	Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results	NASDAQ:AKLI	Akili Inc
06/03/2024	22h28	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:AKLI	Akili Inc
06/03/2024	22h11	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:AKLI	Akili Inc
06/03/2024	22h07	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:AKLI	Akili Inc
29/02/2024	22h01	Business Wire	Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:AKLI	Akili Inc
27/02/2024	08h00	Business Wire	PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan	NASDAQ:AKLI	Akili Inc
26/02/2024	14h47	Business Wire	Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan	NASDAQ:AKLI	Akili Inc
23/02/2024	23h28	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:AKLI	Akili Inc
23/02/2024	13h57	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:AKLI	Akili Inc
21/02/2024	22h05	Business Wire	Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates	NASDAQ:AKLI	Akili Inc
18/12/2023	14h00	Business Wire	EndeavorRxⓇ, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17	NASDAQ:AKLI	Akili Inc
09/11/2023	22h02	Business Wire	Akili Reports Third Quarter 2023 Financial Results and Provides Business Update	NASDAQ:AKLI	Akili Inc
19/10/2023	18h27	Business Wire	Akili to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 9 at 4:30 p.m. ET	NASDAQ:AKLI	Akili Inc
12/10/2023	14h00	Business Wire	Employees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study Finds	NASDAQ:AKLI	Akili Inc
06/10/2023	13h00	Business Wire	Akili Announces Leadership Transition	NASDAQ:AKLI	Akili Inc
27/09/2023	13h45	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	NASDAQ:AKLI	Akili Inc
21/09/2023	14h00	Business Wire	Akili Releases EndeavorOTC™ on Android™ Devices, Expanding Treatment Access for Millions of Adults with ADHD	NASDAQ:AKLI	Akili Inc
13/09/2023	14h11	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:AKLI	Akili Inc
13/09/2023	14h00	Business Wire	Akili Announces Business Transformation, Focusing on Non-prescription Model	NASDAQ:AKLI	Akili Inc
10/08/2023	22h01	Business Wire	Akili Reports Second Quarter 2023 Financial Results and Provides Business Update	NASDAQ:AKLI	Akili Inc
10/07/2023	13h00	Business Wire	Akili to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 10 at 4:30 p.m. ET	NASDAQ:AKLI	Akili Inc
07/06/2023	13h13	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:AKLI	Akili Inc
07/06/2023	13h07	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:AKLI	Akili Inc
07/06/2023	13h00	Business Wire	Akili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHD	NASDAQ:AKLI	Akili Inc
31/05/2023	13h00	Business Wire	Akili to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with ADHD at 2023 ASCP Annual Meeting and Elevate Psych Congress	NASDAQ:AKLI	Akili Inc
11/05/2023	22h01	Business Wire	Akili Reports First Quarter 2023 Financial Results and Provides Business Update	NASDAQ:AKLI	Akili Inc